Aren Karapetyan, Radiation Oncologist, Research Fellow at Immune Oncology Research Institute and Content Editor at OncoDaily, shared a post on LinkedIn:
“At ESMO2025, Jingjing Miao reported phase III trial (NCT02973386), showing that adjuvant capecitabine after CCRT can strengthen long-term outcomes vs CCRT alone—bringing a pragmatic step to “finish strong” after chemoradiation.”
